Allegro NV, a biomedical company developing transformative nanotechnology-based treatments for degenerative joint disease, has found that hydrocelin (ALG-001), its injectable microparticle hydrogel, showed no signs of toxicity in two preclinical studies conducted for periods of 4 and 13 weeks respectively.
